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ABSTRACT
Objectives: To evaluate the initial functional results and 
early complication rate of ceramic-ceramic total hip repla-
cements among patients living with HIV who presented 
osteonecrosis of the femoral head. Method: Twelve HIV-
-positive patients with a diagnosis of osteonecrosis of the 
incongruent femoral head were evaluated using clinical and 
laboratory criteria and the WOMAC functional scale before 
and after treatment with joint replacement. Results: We 
observed that 83.3% of the subjects were taking protease 
inhibitors, 75% had dyslipidemia and 66.6% had lipodys-
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INTRODUCTION
It has been estimated that around 630,000 people 
are living with HIV or AIDS in Brazil and, according 
to the parameters of the World Health Organization, 
this country has one of the highest concentrations of 
the epidemic, with a prevalence of HIV infection of 
0.61% among the population aged 15 to 49 years(1).
The treatments available do not provide a cure and 
present variable efficiency and adverse effects. Thus, 
prevention is the best method of avoiding HIV infec-
tion and AIDS, and their consequences.
Studies have indicated that the prevalence of osteo-
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trophy syndrome. The improvement over the evolution of 
the WOMAC score was statistically significant at six and 
twelve months after the operation, in comparison with the 
preoperative score. We did not observe complications se-
condary to this procedure. Conclusion: Total hip arthroplas-
ty with a ceramic-ceramic implant for treating avascular 
necrosis of the hip is an appropriate surgical option for this 
portion of the population. It provides a significant initial 
functional improvement and a low early complication rate.
Keywords – HIV; Femur Head Necrosis; Arthroplasty; 
Dyslipidemias
articular alterations among patients living with HIV/
AIDS is high, and that the presence of the virus and 
highly active antiretroviral therapy are independent 
risk factors that are boosted by associated metabolic 
and immunological disorders(2,3). 
Osteonecrosis of the femoral head has an estimated 
annual incidence of 4% in this population, and mean 
bilaterality of 57%. This is of concern because it affects 
a young group of patients, between their fourth and 
fifth decades of life, and presents evolution to collapse 
of the head and permanent partial incapacity in 80% of 
the cases that have had the disease for four years(3-7).
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and joint surfaces (in the acetabulum and femo-
ral head) made of ceramic, zirconium and alumina 
(Johnson & Johnson®).
There were no intraoperative difficulties. Dissec-
tion of the soft tissues was facilitated by the small 
thickness of the adipose layer, a frequent character-
istic of this population, which enabled adequate joint 
exposure through a small surgical incision. Manipula-
tion of the bone tissue did not present indications of 
fragility with regard to cutting, milling and implant 
fixation (Figures 1, 2 and 3).
The acetabular component and the femoral nail 
were implanted under pressure (press fit), and com-
plementary screws were used in the acetabulum in 
order to allow immediate loading (Figures 4 and 5).
Bone tissue from the femoral head, acetabulum 
and joint capsule were sent for anatomopathological 
examination and culturing to test for aerobic and an-
aerobic bacteria, fungi and mycobacteria.
A double-lumen Porto-Vac® drain of size 3.2 was 
used in all the patients and was removed on the second 
postoperative day. Standardized antimicrobial prophy-
laxis was used, consisting of 1.5 g of intravenous cefu-
roxime (Zinacef®) every 12 hours for 24 hours.
The patients were kept with an abduction pad on 
the lower limbs until the first day after the operation. 
Physiotherapy was started immediately after the 
operation, while avoiding active adduction of the hip 
for three weeks.
The mean length of hospital stay was four days, and 
there was no need for support in an intensive care unit.
The patients were released for progressive partial 
Figure 1 – Joint exposure of the left hip showing high degree of compro-
mising of the femoral head.
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The diagnosis is suspected based on the patient’s 
history and appropriate physical examination, and 
early diagnosis is achieved by means of investigation 
using magnetic resonance imaging(3).
The treatment options, which depend on the stage 
of evolution of the disease, include: motor physio-
therapy to maintain joint movement and strengthen 
muscles; removal of weight-bearing from the affected 
limb; drug therapy using bisphosphonates; electrical 
therapy; bone decompression; and partial or total joint 
replacement(3-5).
The present authors recently performed 12 total hip 
arthroplasty procedures secondary to osteonecrosis of 
the femoral head in patients living with HIV/AIDS. 
This article is based on our experience and focuses 
on the preoperative planning, care during the surgical 
procedure, postoperative complications and initial re-
sults from follow-up of more than 12 months.
MATERIALS AND METHODS
After obtaining approval from the Scientific 
Committee of the Institute of Orthopedics and 
Traumatology (IOT), University of São Paulo (USP), 
and from the Ethics Committee of Hospital das Clínicas, 
USP, under number 0606/08, 12 HIV-positive patients 
who were being followed up as cases of hip osteonecrosis 
were operated by the Osteo-HIV group of IOT-HC-
FMUSP between September and December 2009. 
The inclusion criteria were the following: 1) posi-
tive serological test for HIV; 2) adherence to anti-
retroviral treatment at state care centers; 3) clinical 
release for the procedure after infectology assess-
ment; 4) symptomatic hip osteonecrosis confirmed 
by means of magnetic resonance imaging; and 5) loss 
of sphericity of the femoral head. 
All the patients underwent assessment of the clini-
cal and laboratory criteria and measurement of the 
WOMAC score(8).
All the patients were operated in lateral decubitus 
under regional anesthesia (spinal anesthesia). The 
route used was the Hardinge lateral approach(9), by 
means of dissection of the tendons of the gluteus 
medius and vastus lateralis muscles. The joint cap-
sule was preserved in all the procedures. The mean 
duration of the procedures was 122 minutes (range: 
80 to 155 minutes).
The implants used were uncemented total pros-
theses, with a Summit nail, Pinnacle acetabulum 
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loading on the first day after the arthroplasty, and full 
loading was reached in three weeks.
Low molecular weight heparin (Clexane®) at a 
dose of 40 mg/day was used for 21 days in order to 
prevent thromboembolic events.
The stitches were removed at the first outpatient 
return visit, 10 days after the operation. Outpatient 
Figure 2 – Acetabular surface after milling.
Figure 3 – Placement of the femoral nail under pressure (press fit).
Figure 4 – Anteroposterior radiograph of the left hip showing fixation of the 
femoral and acetabular components.
Figure 5 – Expanded anteroposterior radiographic view of the left hip sho-
wing good metaphyseal fixation of the femoral nail and distribution of the 
fixation screws of the acetabular component.
follow-ups were done 10 days, one month, three 
months and six months after the surgery.
Table 1 describes the laboratory data, disease history 
and use of antiretroviral medication among the sample.
Chart 1 describes the demographic characteristics, 
means of the laboratory findings, disease history and 
use of antiretroviral medication.
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RESULTS
The patients’ mean WOMAC scores before the 
operation and six and twelve months after the opera-
tion were respectively 64.2, 19.3 and 10.3, as shown 
in Chart 2.
DISCUSSION 
Avascular necrosis of the femoral head is a disease 
secondary to compromising of the vascular system of 
the proximal region of the femur. Although many pa-
tients do not present any specific identified etiological 
factor, the risk factors and conditions have been well 
determined in the literature(10).
The incidence of osteonecrosis of the femoral 
head in the general population ranges from 0.010 to 
0.135%, while in the HIV-positive population it ran-
ges from 1.33 to 4.4%(3,11,12).
The Osteo-HIV service of the Institute of Orthope-
Table 1 – Distribution of the laboratory parameters, periods of disease 
duration and use of antiretroviral medication among the sample.
(months) CD4 (cell/mm3)
Disease 
duration 
(months)
Viral load 
(copies/
mL)
Duration of 
medication 
use
Patient 1 415 120 < 50 120
Patient 2 373 84 < 50 82
Patient 3 563 164 Undetectable 121
Patient 4 290 180 Undetectable 132
Patient 5 892 168 60 168
Patient 6 614 132 Undetectable 132
Patient 7 371 228 Undetectable 192
Patient 8 586 72 71 72
Patient 9 147 132 Undetectable 96
Patient 10 428 72 Undetectable 72
Patient 11 221 120 Undetectable 48
Patient 12 445 96 Undetectable 96
Chart 1 – Demographic, laboratory and clinical data of the sample.
Mean age 45 years (range: 32 to 65)
Gender Male (n = 11)/female (n = 1)
Side affected Bilateral (n = 6)/unilateral (n = 6)
Mean CD4 lymphocyte count 454 cells/ml (147 to 892)
Viral load Undetectable (n = 9)
Mean length of time with HIV 131 months (72 to 228)
Mean length of time using 
antiretroviral therapy 131 months (72 to 192)
*TARV = terapia antirretroviral.
Chart 2 – WOMAC score before the operation and after six and twelve 
months of follow-up, and presence of dyslipidemia and lipodystrophy. 
Patient
WOMAC score before 
operation and after 
six and 12 months of 
follow-up
(before/six/twelve)
Dyslipidemia Lipodystrophy
1 71/21/3 + +
2 89/19/19 - +
3 66/19/13 + +
4 45/7/7 - -
5 73/32/15 + -
6 64/26/16 + +
7 48/24/1 + +
8 46/15/1 + +
9 64/17/13 + +
10 80/34/26 + -
11 57/4/4 + -
12 68/14/6 - +
dics and Traumatology of USP had 983 patients under 
follow-up; 11% of this group presented complaints 
relating to the coxofemoral joint, and 65 patients were 
treated for avascular necrosis of the femoral head.
Among patients living with HIV, viral infection 
and antiretroviral therapy are independent risk factors. 
The presence of hypertriglyceridemia, anticardiolipin 
antibodies and lipodystrophic syndrome and use of 
protease inhibitors increase the risk of developing 
osteonecrosis(3-5).
In the sample presented, we found that 83.3% were 
using protease inhibitors, 75% had dyslipidemia and 
66.6% had lipodystrophic syndrome, and these findings 
were concordant with data in the literature.
The surgical technique used was the Hardinge ap-
proach. Despite the high prevalence of osteopenia 
and osteoporosis in this population of patients, we did 
not observe any technical difficulty in implanting the 
prosthetic components, and the osseointegration ob-
served in the outpatient control radiographs presented 
normal patterns(13-16). 
The patients’ young age group, high demand on 
the joints and risk of harm to renal function due to 
release of metal particles explain why joint surfaces 
made of ceramic and uncemented acetabular and fe-
moral components made of porous metal are chosen. 
These characteristics provide high durability for the 
implants, with preservation of the bone stock, longer 
intervals until surgical revision is needed, low pro-
duction of joint metalosis, low incidence of aseptic 
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loosening and low systemic and local risks(12,17,18).
The decreases in WOMAC score among these 
patients, six and twelve months after the operation, 
demonstrate that there were significant improvements 
regarding pain, locomotor function and quality of life. 
Moreover, these indicate postoperative evolution that 
is as fast as or faster than that of the general popu-
lation, possibly due to the young age group of the 
sample of the present study(19-21).
We did not observe any postoperative complica-
tions, although data in the literature indicate infection 
rates after this procedure in patients living with HIV 
ranging from 14 to 1.85%(6,22,23).
CONCLUSION
Total hip arthroplasty using a ceramic-ceramic 
implant to treat avascular necrosis of the hip in HIV-
-positive patients with a collapsed femoral head was 
shown to be an adequate surgical option, presenting 
significant initial functional improvement and a low 
early complication rate.
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